Skip to main
INBX
INBX logo

INBX Stock Forecast & Price Target

INBX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company that is well capitalized with $152.6 million in cash, positioning it effectively for continued development of its lead candidates, INBRX-109 and INBRX-106, which target key therapeutic areas. The anticipated readouts for these candidates in late 2025 highlight the potential for significant value generation from its proprietary protein engineering platforms. Despite a reported earnings per share of ($3.09) in the fourth quarter of 2024, the company's substantial cash reserves provide a solid foundation for future growth and strategic advancements.

Bears say

Inhibrx Biosciences has reported minimal revenues of $100K for 4Q24, which raises concerns about its ability to generate significant income amid high research and development expenses of $33.4MM and selling, general, and administrative costs of $16.7MM—both exceeding estimates. The company faces substantial risk due to a lack of differentiating clinical data, the possibility of clinical trial failures, and potential delays in drug approvals, all of which could adversely affect its stock price. Additionally, the generic nature of the clinical assets within a competitive landscape further heightens the uncertainty regarding the overall market potential of its therapeutic candidates.

INBX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inhibrx Biosciences Inc (INBX) Forecast

Analysts have given INBX a Buy based on their latest research and market trends.

According to 5 analysts, INBX has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inhibrx Biosciences Inc (INBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.